BioCentury
ARTICLE | Company News

Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

September 21, 2018 6:27 PM UTC

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Sept. 20 that partner Celgene Corp. (NASDAQ:CELG) will not exercise its option to license OncoMed's bispecific antibody navicixizumab (OMP-305B83) as a result of "strategic product portfolio considerations."

The bispecific targeting delta-like 4 (DLL4) and VEGF is in Phase Ib testing in combination with paclitaxel for platinum-resistant late-stage ovarian cancer. Interim data will be presented next month...